On behalf of Genentech, Inc., I respectfully request the NCCN Non-Hodgkin’s Lymphoma Guideline Panel to review the enclosed recent key presentation and poster for:

- **Gazyva® (obinutuzumab):** Untreated or relapsed/refractory CLL
  

- **Gazyva® (obinutuzumab):** Previously untreated CLL
  

**Specific Changes:**
Please consider the Goede et al. and Stilgenbauer et al. for your updating purposes.

**FDA Clearance:**
Gazyva is FDA approved in combination with chlorambucil for the treatment of patients with previously untreated CLL.

Please refer to the product prescribing information for the full FDA-approved indications and safety information.


**Rationale:**

Goede et al.: The GREEN study is an ongoing, non-randomized, multi-cohort Phase 3b study designed to evaluate Gazyva alone or in combination with chemotherapy in patients with previously untreated or relapsed/refractory CLL. Safety was the primary endpoint. Safety and efficacy from Cohort 1 (n=158) in patients with previously untreated CLL who received Gazyva + bendamustine were recently presented at the ASH congress. The most common Grade ≥3 adverse events (AEs) included neutropenia (50%), infusion related reactions (15.2%), infections (12.7%), thrombocytopenia (12.7%), tumor lysis syndrome (10.1%), and hemorrhagic events (0.6%). Response rates are shown in the table below.
## GREEN Phase 3b Study Response to Therapy from Patients in Cohort 1

<table>
<thead>
<tr>
<th></th>
<th>All Patients (n=158)</th>
<th>Fit Patients (n=74)</th>
<th>Non-Fit† Patients (n=84)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORR, %</td>
<td>78.5</td>
<td>81.1</td>
<td>76.2</td>
</tr>
<tr>
<td>CR/CRi, %</td>
<td>32.3</td>
<td>29.7</td>
<td>34.5</td>
</tr>
<tr>
<td>PR, %</td>
<td>46.2</td>
<td>51.4</td>
<td>41.7</td>
</tr>
<tr>
<td>SD, %</td>
<td>10.8</td>
<td>10.8</td>
<td>10.7</td>
</tr>
<tr>
<td>PD, %</td>
<td>0.6</td>
<td>0</td>
<td>1.2</td>
</tr>
<tr>
<td>Missing, %</td>
<td>10.1</td>
<td>8.1</td>
<td>11.9</td>
</tr>
</tbody>
</table>

Notes: * Patients with CrCl>70 mL/min and CIRS score ≤6. † Patients with CrCl <70 mL/min and CIRS score >6.

Abbreviations: CIRS=Cumulative Illness Rating Scale; CrCl=creatinine clearance; CR=complete response; CRi=complete response with incomplete hematologic recovery; ORR=overall response rate; PD=progressive disease; PR=partial response; SD=stable disease

Minimal residual disease (MRD), a secondary endpoint, was assessed in patients with evaluable samples at 3 months end-of-treatment. In the intent-to-treat population, MRD-negativity was 58.9% (93/158) in the peripheral blood and 27.8% (45/158) in the bone marrow.

An additional study has been conducted to evaluate Gazyva + bendamustine in CLL.¹

### Stilgenbauer et al.:  
The CLL11 study was a Phase 3, open-label, randomized, 2-stage, 3-arm trial that was conducted to compare the safety and efficacy of Gazyva with chlorambucil (G-Clb) vs chlorambucil (Clb) alone (Stage 1a) and vs Rituxan with Clb (R-Clb; [Stage 2]) in patients with previously untreated CLL. Results from these studies were previously submitted.²⁴ The updated interim analysis of the CLL11 study showed that after a median observation time of 42.4 months, median progression-free survival (PFS) was 31.1 months in the G-Clb arm and 11.1 months in the Clb arm (hazard ratio [HR]=0.20; 95%CI, 0.15-0.26; p<0.0001). The median time to new anti-leukemic treatment (TTNT) was 51.1 months in the G-Clb arm and 15.1 months in the Clb arm (HR=0.24; 95% CI, 0.17-0.34; p<0.0001). Median overall survival (OS) was not reached in the G-Clb arm and 58.5 months in the Clb arm (HR=0.62; 95% CI, 0.42-0.92; p=0.0167). For Stage 2, after a median observation time of 39 months, the median PFS was 28.7 months in the G-Clb arm vs 15.7 months in the R-Clb arm (HR=0.46; 95%CI, 0.38-0.55; p<0.0001). The median TTNT was 51.1 months in the G-Clb arm vs 38.2 months in the R-Clb arm (HR=0.57; 95% CI, 0.44-0.74; p<0.0001). The OS analysis for G-Clb vs R-Clb reported a hazard ratio of 0.77 (95% CI, 0.57-1.05; p=0.0932). Median OS had not been reached in either arm. No new safety signals were reported.

Any references supplied to you are protected under U. S. Copyright Law (Title 17, U.S. Code). No further reproduction is permitted.

Respectfully submitted,

Danielle Dishmon, Pharm.D.

### Supplemental References

2. Goede V, Fischer K, Humphrey K, et al. Obinutuzumab (GA101) + chlorambucil (Clb) or rituximab (R) + Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities): final stage 1 results of the CLL11 (BO21004) Phase 3 trial.
Presented at the American Society of Clinical Oncology 2013 Annual Meeting in Chicago, IL; May 31–June 4, 2013. ASCO Oral Presentation.


C#15-M0125